• FDA clearance and CMS reimbursement for CT:VQ technology
• Rapid adoption by top U.S. Academic Medical Centers
• Expanded regulatory footprint across six jurisdictions
• Strong financial performance with 21% revenue growth
• Strategic partnerships with pharmaceutical companies

4DMedical Ltd announced its FY26 Full Year Results, highlighting significant commercial and clinical achievements for its CT:VQ technology. The FDA cleared CT:VQ in September 2025, making it the first non-contrast, CT-based ventilation-perfusion imaging technology. U.S. Centers for Medicare & Medicaid Services confirmed reimbursement at US$650.50 per scan. The technology was adopted by top U.S. Academic Medical Centers and entered the U.S. outpatient market through a contract with SimonMed Imaging. CT:VQ was authorized in the European Union, United Kingdom, Canada, New Zealand, and Australia, expanding its regulatory footprint. The technology was also commercialized in Australia, with contracts secured with multiple imaging providers. CT:VQ demonstrated its effectiveness in improving lung volume reduction surgery patient selection, with responder rates increasing from 46% to 76%. The company launched a clinical evidence program to enter the acute pulmonary embolism market. Strategic partnerships with AstraZeneca and GlaxoSmithKline supported lung health screening programs and pulmonary drug development. In Europe, 4DMedical secured a significant lung cancer screening contract in Germany and appointed Alexander Albert as Vice President Sales, Europe.

Operating revenue for FY26 was $7.1m, up 21% vs FY25, with strong margins exceeding 90%

The company anticipates continued growth driven by the expansion of CT:VQ technology and strategic partnerships.